Zhaozhong Jon Jia

This inventor holds 41 USPTO granted patents and 18 published patent applications, plus 6 CIPO patents and 10 EPO patents, primarily in Kinase Inhibitors. Top assignees: Portola Pharmaceuticals, Inc., Millennium Pharmaceuticals Limited, Pharmacyclics, Inc.. Active years: 2002-2024.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhaozhong Jon Jia. Retrieved from https://idiyas.com/inventor/zhaozhong-jon-jia

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 41 (Patent Applications = 18)

% Patents Active = 73.2

CIPO Patents = 6 (Patent Applications = 8)

EPO Patents = 10 (Patent Applications = 14)

Average Co-Inventor Count = 5.8

ph-index = 12

Forward Citations = 526(Granted Patents)

Location History:

South San Franscisco, CA (US) (2003)
South San Francisco, CA (US) (2002 - 2004)
So. San Francisco, CA (US) (2004)
San Mateo, CA (US) (2006 - 2022)

Company Filing History:

18 out of 71

Portola Pharmaceuticals, Inc.

patents

14 out of 855

Millennium Pharmaceuticals Limited

Alexion Pharmaceuticals, Inc.

patents

6. 1 out of 92

Cor Therapeutics, Inc.

patents

Years Active: 2002-2024

Loading Chart...

Areas of Expertise:

Bruton's Tyrosine Kinase

Protein Kinases

Syk Modulators

JAK Kinase

Pyrimidines

Purinone Compounds

Factor Xa

Benzamides

Nicotinamides

Pyrazine

Triazine Compounds

Dioxo-3-Quinazolinyl

41 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12172992 - Pyrimidines for degrading Bruton's tyrosine kinase (2024-12-24),

2. 11414410 - Inhibitors of protein kinases (2022-08-16),

3. 10533001 - Inhibitors of protein kinases (2020-01-14),

4. 9902688 - Benzamides and nicotinamides as Syk modulators (2018-02-27),

5. 9676756 - Substituted pyrimidinyl kinase inhibitors (2017-06-13),

6. 9656988 - Inhibitors of Bruton's tyrosine kinase (2017-05-23),

7. 9637487 - Purinone compounds as kinase inhibitors (2017-05-02),

8. 9624224 - Inhibitors of Bruton's tyrosine kinase (2017-04-18),

9. 9580416 - Inhibitors of Bruton's tyrosine kinase (2017-02-28),

10. 9579320 - Inhibitors of syk and JAK protein kinases (2017-02-28),

11. 9533991 - Inhibitors of Bruton's tyrosine kinase (2017-01-03),

12. 9382246 - Inhibitors of Bruton's tyrosine kinase (2016-07-05),

13. 9359375 - Benzamides and nicotinamides as Syk modulators (2016-06-07),

14. 9359308 - Pyrazine kinase inhibitors (2016-06-07),

15. 9139581 - Inhibitors of protein kinases (2015-09-22),

Certainly! Here is an article about inventor Zhaozhong Jon Jia based on the given data:

Title: Innovator Spotlight: Zhaozhong Jon Jia - Pioneering Pathways in Medicine

Introduction:

Zhaozhong Jon Jia, a distinguished inventor based in San Mateo, CA (US), has made significant contributions to the field of medicine with a remarkable portfolio of 40 patents.

Latest Patents:

Jia's latest patents revolve around groundbreaking innovations in the treatment of multiple myeloma. His inventions include inhibitors of protein kinases, specifically compounds of Formula (I) or their pharmaceutically acceptable salts. These inhibitors demonstrate promising results in targeting syk and JAK kinase activity, offering new avenues for treating various medical conditions.

Career Highlights:

Throughout his career, Jia has been associated with leading pharmaceutical companies such as Portola Pharmaceuticals, Inc. and Millennium Pharmaceuticals Limited. His expertise and innovative spirit have been instrumental in driving advancements in the healthcare industry.

Collaborations:

Jia has collaborated closely with esteemed colleagues in his research endeavors. Noteworthy among them are his coworkers Yonghong Song and Shawn M Bauer, who have worked alongside him in various projects, contributing to the success of his inventive endeavors.

Conclusion:

Inventor Zhaozhong Jon Jia stands as a beacon of innovation in the realm of medicine, with a prolific patent portfolio and a track record of pioneering contributions. His relentless pursuit of excellence and commitment to advancing medical treatments underscore his significant impact on the field.

Profile summary based on public USPTO records.